Developing new drugs to treat serious fungal infections
A Redesigning Existing Drugs against Indispensable Targets (ReEDIT) platform technology for discovery of novel drugs to treat fungal infections
This study is working on making better medicines for serious fungal infections, like those caused by Candida albicans, by redesigning current drugs to target important genes in the fungi, so that people can have more effective treatments, especially if their infections are resistant to existing options.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kathera Bioscience INC. NIH-funded |
| Lab location | 1 site (Union, United States) |
| Project ID | NIH-10906002 on NIH RePORTER |
What this research studies
This research focuses on improving treatments for life-threatening fungal infections by redesigning existing drugs to target essential genes in fungi like Candida albicans. The approach involves identifying druggable targets that are crucial for fungal survival and using a combination of biochemical, structural, and bioinformatics techniques to develop new antifungal therapies. By leveraging known inhibitors and advanced modeling studies, the project aims to create more effective treatments that can overcome current drug resistance issues.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from systemic fungal infections, particularly those caused by Candida species.
Not a fit: Patients with fungal infections that are not caused by Candida or those who do not respond to antifungal treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel antifungal drugs that are more effective against resistant fungal infections.
How similar studies have performed: Previous research has shown promise in targeting essential genes in fungi, indicating that this approach could lead to significant advancements in antifungal treatments.
Where this research is happening
Union, United States
- Kathera Bioscience INC. — Union, United States (Active)
Researchers
- Principal investigator: Parent, Stephen — Kathera Bioscience INC.
- Study coordinator: Parent, Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.